Detalles de la búsqueda
1.
Induction of SGK1 via glucocorticoid-influenced clinical outcome of triple-negative breast cancer patients.
Breast Cancer Res Treat
; 200(3): 323-335, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37286891
2.
Satisfaction of Patients Who Received Breast-Conserving Surgery Using the Suture Scaffold Technique: A Single-Institution, Cross-Sectional Study.
Ann Surg Oncol
; 29(6): 3829-3835, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35275329
3.
Significance of glucocorticoid signaling in triple-negative breast cancer patients: a newly revealed interaction with androgen signaling.
Breast Cancer Res Treat
; 180(1): 97-110, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31989378
4.
Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy.
Breast Cancer Res Treat
; 173(2): 275-288, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30306430
5.
Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer.
Future Oncol
; 15(21): 2489-2501, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31140297
6.
Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients.
Int J Clin Oncol
; 24(3): 262-273, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30392115
7.
Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial.
Breast Cancer Res Treat
; 161(3): 473-482, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28005247
8.
Effects of cytokines derived from cancer-associated fibroblasts on androgen synthetic enzymes in estrogen receptor-negative breast carcinoma.
Breast Cancer Res Treat
; 166(3): 709-723, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28831645
9.
ASO Author Reflections: Patients' Satisfaction After Breast Conserving Surgery Using the Suture Scaffold Technique.
Ann Surg Oncol
; 29(6): 3836-3837, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35266082
10.
Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies.
Breast Cancer Res Treat
; 158(1): 1-9, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27260189
11.
Intratumoral estrogen production and actions in luminal A type invasive lobular and ductal carcinomas.
Breast Cancer Res Treat
; 156(1): 45-55, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26943913
12.
Tumor microenvironment in invasive lobular carcinoma: possible therapeutic targets.
Breast Cancer Res Treat
; 155(1): 65-75, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26715212
13.
A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer.
Jpn J Clin Oncol
; 46(5): 407-14, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26917603
14.
Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.
Support Care Cancer
; 23(4): 1137-43, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25576433
15.
Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer.
Int J Clin Oncol
; 20(6): 1102-9, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25967286
16.
Intratumoral androgen metabolism and actions in invasive lobular carcinoma of the breast.
Cancer Sci
; 105(11): 1503-9, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25230018
17.
Long-term prognostic value of the GenesWell BCT score in Asian women with hormone receptor-positive/HER2-negative early breast cancer.
Breast Cancer
; 31(1): 31-41, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37812303
18.
The Clinicopathological and Prognostic Significance of HER2-Low Breast Cancer: A Comparative Analysis Between HER2-Low and HER2-Zero Subtypes.
Clin Breast Cancer
; 2024 Feb 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38472058
19.
A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer.
Breast Cancer Res Treat
; 139(2): 441-51, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23715630
20.
A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study).
Int J Clin Oncol
; 18(4): 598-606, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22833344